Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients

Before licensing, ipilimumab was first made available to previously treated advanced melanoma patients through an expanded access programme (EAP) across Europe. We interrogated data from UK EAP patients to inform future clinical practice. Clinicians registered in the UK EAP provided anonymized patie...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	S Ahmad, S, Qian, W, Ellis, S, Mason, E, Khattak, M, Gupta, A, Shaw, H, Quinton, A, Kovarikova, J, Thillai, K, Rao, A, Board, R, Nobes, J, Dalgleish, A, Grumett, S, Maraveyas, A, Danson, S, Talbot, T, Harries, M, Marples, M, Plummer, R, Kumar, S, Nathan, P, Middleton, M, Larkin, J, Lorigan, P, Wheater, M, Ottensmeier, C, Corrie, P
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	Lippincott, Williams and Wilkins 2015

Antzeko izenburuak

Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study.
nork: Lorigan, P, et al.
Argitaratua: (2014)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
nork: Dalle, S, et al.
Argitaratua: (2021)

Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab
nork: M. Hardy-Werbin, et al.
Argitaratua: (2018-02-01)

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
nork: Gupta, A, et al.
Argitaratua: (2014)

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
nork: Gupta, A, et al.
Argitaratua: (2013)

Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
nork: Dalle, S, et al.
Argitaratua: (2019)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
nork: Revicki Dennis A, et al.
Argitaratua: (2012-06-01)

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
nork: Max Hardy-Werbin, et al.
Argitaratua: (2019-06-01)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
nork: Bart Neyns, et al.
Argitaratua: (2022-07-01)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
nork: A. A. Formozo, et al.
Argitaratua: (2021-01-01)

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
nork: Urbonas, V, et al.
Argitaratua: (2018)

Results of combined nivolumab and ipilimumab therapy in patients with cancer
nork: M. A. Lyadova, et al.
Argitaratua: (2021-12-01)

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
nork: Middleton, M, et al.
Argitaratua: (2016)

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma
nork: M. N. Khagazheeva, et al.
Argitaratua: (2022-06-01)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
nork: Joanne M. Jeter, et al.
Argitaratua: (2012-01-01)

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
nork: W. J. Mullally, et al.
Argitaratua: (2022-04-01)

The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK.
nork: James Larkin, et al.
Argitaratua: (2015-01-01)

First-line Nivolumab plus Ipilimumab in patients with advanced melanoma previously treated with adjuvant systemic therapy
nork: K. Kisielewska, et al.
Argitaratua: (2024-01-01)

Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab
nork: Quaovi H Sodji, et al.
Argitaratua: (2020-05-01)

Panhypopituitarism induced by ipilimumab
nork: Miyu Shiratori, et al.
Argitaratua: (2020-01-01)

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
nork: O'Brien, M, et al.
Argitaratua: (2013)

IgA Nephropathy Secondary to Ipilimumab Use
nork: Sean C. Dougherty, et al.
Argitaratua: (2021-11-01)

Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes
nork: Chen P, et al.
Argitaratua: (2018-07-01)

Acute visual loss after ipilimumab treatment for metastatic melanoma
nork: Melissa A. Wilson, et al.
Argitaratua: (2016-11-01)

Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
nork: Weber, J, et al.
Argitaratua: (2019)

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
nork: Ian M. Bouligny, et al.
Argitaratua: (2025-02-01)

IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA
nork: I. V. SAMOILENKO, et al.
Argitaratua: (2016-12-01)

Ipilimumab-Induced Neutropenia in Melanoma
nork: Makiko Ban-Hoefen MD, et al.
Argitaratua: (2016-08-01)

Ipilimumab induced digital vasculitis
nork: Amrita Padda, et al.
Argitaratua: (2018-02-01)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
nork: Celeste Lebbe, et al.
Argitaratua: (2023-05-01)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
nork: William L Redmond, et al.
Argitaratua: (2021-10-01)

Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab
nork: Alexandre Reuben, et al.
Argitaratua: (2017-12-01)

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
nork: Lipplaa, A, et al.
Argitaratua: (2018)

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
nork: Remon J, et al.
Argitaratua: (2019-05-01)

Feasibility and efficacy of preoperative ipilimumab/nivolumab in loco-regionally advanced urothelial cancer of the bladder (NABUCCO)
nork: B.W.G. Van Rhijn, et al.
Argitaratua: (2020-07-01)

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
nork: Dangoor, A, et al.
Argitaratua: (2010)

Ipilimumab and nivolumab in uveal melanoma: report on toxicity and treatment intensity
nork: A. Ciernik, et al.
Argitaratua: (2024-01-01)

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
nork: Priscilla K. Brastianos, et al.
Argitaratua: (2021-10-01)

Engineered ipilimumab variants that bind human and mouse CTLA-4
nork: Brett Robison, et al.
Argitaratua: (2025-12-01)

Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas
nork: Santosh Kesari, et al.
Argitaratua: (2024-12-01)